KFDA explained about KCPB's hazardous drug issues.

Published: 2004-05-17 06:58:00

Updated: 2004-05-17 06:58:00

Korea Consumer Protection Board (KCPB) recently released a report to the public under the title of "Domestic sales of drugs feared with serious adverse reactions", for which KFDA made it clear that it was not new for physicians, pharmacists and consumers any longer and already well treated in the...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK